Modulus Oncology Ltd (Modulus) is an innovative spinout company created by a founding team of scientists from the University of Sheffield (TUOS) and an impressive lineup of successful biotech entrepreneurs. Modulus has developed first-in-class antagonists of a G protein-coupled receptor, the adrenomedullin 2 receptor (AM2R), for the treatment of cancer. The research underpinning Modulus arose from a sophisticated drug discovery project made possible by the Wellcome Trust’s (WT) ‘seeding drug discovery’ initiative. The deep scientific insights of the TUOS founding team into the biology of the AM2R), in tandem with a collaborative academic and pharma industry drug discovery approach, has resulted in the exciting small molecule asset portfolio of AM2R antagonists at Modulus.